24/7 Market News Snapshot 14 October, 2025 – Rocket Pharmaceuticals, Inc. Common Stock (NASDAQ:RCKT)

October 14, 2025

DENVER, Colo., 14 October, 2025 (www.247marketnews.com) – (NASDAQ:RCKT) are discussed in this article.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a pioneer in developing innovative genetic therapies for rare disorders, has seen a significant boost in its stock price, reflecting strong investor sentiment. Opening at $3.92, shares have surged to $4.075, marking a 17.44% increase from the previous session’s close of $3.47. This uptick, driven by heightened interest and positive market trends, has resulted in a trading volume of 5.86 million shares. Investors are encouraged to keep a close watch on technical indicators, including the Relative Strength Index (RSI) and moving averages, as this bullish momentum may present potential investment opportunities.

Adding to the excitement, the FDA has accepted the resubmission of Rocket’s Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a pioneering gene therapy targeting severe Leukocyte Adhesion Deficiency-I (LAD-I). Currently, this life-threatening genetic immune disorder places patients at a heightened risk of recurrent infections, making prompt therapeutic interventions essential. The FDA has established a new Prescription Drug User Fee Act (PDUFA) date of March 28, 2026, an important step towards making KRESLADI™ accessible to those in need.

Dr. Gaurav Shah, CEO of Rocket Pharmaceuticals, emphasized the company’s commitment to delivering transformative therapies to underserved patient populations. The BLA is backed by compelling clinical data from a global Phase 1/2 study, which revealed a 100% overall survival rate at 12 months post-infusion and a significant decline in severe infections compared to pre-treatment levels. Given the promising results and high safety profile, if approved, KRESLADI™ will also position Rocket to qualify for a Rare Pediatric Disease Priority Review Voucher.

As Rocket ventures forward with its ambitious pipeline aimed at addressing rare diseases, the company remains dedicated to enhancing patient outcomes through groundbreaking medical advancements.

Related news for (RCKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.